The early treatment of type 2 diabetes

American Journal of Medicine

Volumn 126, Issue 9 SUPPL.1, 2013, Pages

  Pratley, Richard E ^a  

^a FLORIDA HOSPITAL   (United States)

Author keywords

Complications; Diabetes prevention trials; Diagnosis; Early intervention; Prediabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ALGORITHM; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DISEASE COURSE; EARLY INTERVENTION; EPIDEMIC; EVIDENCE BASED PRACTICE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 84882283717     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2013.06.007     Document Type: Article

References (80)

1. th ed. Available at: http://www.idf.org/diabetesatlas/5e/diabetes. Accessed May 8, 2013.
2. World Health Organization (WHO). Diabetes fact sheet 312. January 2011. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed May 8, 2013.
3. G. Roglic, and N. Unwin Mortality attributable to diabetes: estimates for the year 2010 Diabetes Res Clin Pract 87 2010 15 19
4. Centers for Disease Control and Prevention (CDC) National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011 2011 U.S. Department of Health and Human Services, Centers for Disease Control and Prevention Atlanta, GA Available at: http://www.cdc.gov/diabetes/pubs/factsheet11.htm Accessed May 8, 2013
5. Ogden CL, Carroll MD. Prevalence of overweight, obesity, and extreme obesity among adults: United States, trends 1960-1962 through 2007-2008. Available at: http://www.cdc.gov/NCHS/data/hestat/obesity-adult-07-08/obesity- adult-07-08.pdf. Accessed May 8, 2013.
6. Centers for Disease Control and Prevention (CDC) Prevalence of overweight and obesity among adults with diagnosed diabetes - United States, 1988-1994 and 1999-2002 MMWR Morb Mortal Wkly Rep 53 2004 1066 1068 Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5345a2.htm Accessed May 8, 2013
7. J.M. Chan, E.B. Rimm, and G.A. Colditz Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men Diabetes Care 17 1994 961 969 (Pubitemid 24268605)
8. G.A. Colditz, W.C. Willett, A. Rotnitzky, and J.E. Manson Weight gain as a risk factor for clinical diabetes mellitus in women Ann Intern Med 122 1995 481 486
9. R. Pratley, and C. Weyer The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus Diabetologia 44 2001 929 945 (Pubitemid 32778125)
10. S.E. Kahn The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes Diabetologia 43 2003 3 19 (Pubitemid 36237741)
11. M. Stumvoll, B.J. Goldstein, and T.W. van Haeften Type 2 diabetes: principles of pathogenesis and therapy Lancet 365 2005 1333 1346
12. A.E. Butler, J. Janson, and S. Bonner-Weir Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes Diabetes 52 2003 102 110 (Pubitemid 36042113)
13. R.A. DeFronzo, M.A. Banerji, and G.A. Bray Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study Diabetologia 53 2010 435 445
14. M. Nauck, B. Baller, and J.J. Meier Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes Diabetes 53 Suppl 3 2004 S190 S196
15. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705 (Pubitemid 46048557)
16. M.A. Nauck, E. Homberger, and E.G. Siegel Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses J Clin Endocrinol Metab 63 1986 492 498 (Pubitemid 16035703)
17. L. Farilla, H. Hui, and C. Bertolotto Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetes rats J Clin Invest 99 1997 2883 2889
18. L. Farilla, A. Bulotta, and B. Hirshberg Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets Endocrinology 144 2003 5149 5158 (Pubitemid 37476040)
19. M. Zander, S. Madsbad, J.L. Madsen, and J.J. Holst Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study Lancet 359 2002 824 830 (Pubitemid 34233752)
20. M.A. Nauck, I. Vardarli, C.F. Deacon, and J.J. Holst Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 54 2011 10 18
21. International Diabetes Federation (IDF) IDF Diabetes Atlas 4th ed. 2009 Available at www.diabetesatlas.org Accessed May 8, 2013
22. D.S. Fong, L. Aiello, and T.W. Gardner Retinopathy in diabetes Diabetes Care 27 Suppl 1 2004 S84 S87
23. A.J.M. Boulton, A.I. Vinik, and J.C. Arezzo Diabetic neuropathies Diabetes Care 28 2005 956 962
24. International Diabetes Federation (IDF). Diabetes and cardiovascular disease: time to act. Available at: http://www.idf.org/webdata/docs/ Diabetes%20and%20CVD.pdf. Accessed May 14, 2013.
25. K.K. Ho, J.L. Pinsky, W.B. Kannel, and D. Levy The epidemiology of heart failure: the Framingham Study J Am Coll Cardiol 22 4 Suppl A 1993 6A 13A (Pubitemid 23285789)
26. I.M. Stratton, A.I. Adler, and H.A. Neil Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 2000 405 412 (Pubitemid 30609442)
27. Y. Ohkubo, H. Kishikawa, and E. Araki Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study Diabetes Res Clin Pract 28 1995 103 117
28. UK Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
29. UK Prospective Diabetes Study Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
30. R.R. Holman, S.K. Paul, and M.A. Bethel 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 2008 1577 1589
31. A. Patel, S. MacMahon, J. Chalmers ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572 (Pubitemid 351831357)
32. H.C. Gerstein, M.E. Miller, R.P. Byington Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559 (Pubitemid 351831356)
33. W. Duckworth, C. Abraira, and T. Moritz VADT Investigators Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2009 129 139
34. J.S. Skyler, R. Bergenstal, and R.O. Bonow Intensive glycaemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Diabetes Care 32 2009 187 192
35. P. Gæde, P. Vedel, H.H. Parving, and O. Pedersen Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study Lancet 353 1999 617 622 (Pubitemid 29087981)
36. P. Gæde, P. Vedel, and N. Larsen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393 (Pubitemid 36159355)
37. B.M.Y. Cheung, K.L. Ong, and S.S. Cherny Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006 Am J Med 122 2009 443 453
38. American Diabetes Association Diagnosis and classification of diabetes mellitus Diabetes Care 34 Suppl 1 2011 S11 S61
39. Centers for Disease Control and Prevention (CDC). More than a third of adults estimated to have prediabetes. Press release January 2011. Available at: http://www.cdc.gov/media/releases/2011/p0126-diabetes.html. Accessed May 8, 2013.
40. C. Lorenzo, K. Williams, K.J. Hunt, and S.M. Haffner The national cholesterol education program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organisation definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes Diabetes Care 30 2007 8 13 (Pubitemid 46052493)
41. A.G. Smith, and J.R. Singleton The diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy Arch Intern Med 164 2004 1021 1025 (Pubitemid 38581524)
42. Diabetes Prevention Program Research Group The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention program Diabet Med 24 2007 137 144
43. T.Y. Wong, G. Liew, and R.J. Tapp Relation between fasting glucose and retinopathy for diagnosis of diabetes: the population-based cross sectional studies Lancet 371 2008 736 743 (Pubitemid 351288874)
44. L. Yanko, U. Goldbourt, and I.C. Michaelson Prevalence and 15-year incidence of retinopathy and associated characteristics in middle-aged and elderly diabetic men Br J Ophthalmol 67 1983 759 765 (Pubitemid 14247742)
45. M. Franciosi, F. Pellegrini, M. Sacco IGLOO (Impaired Glucose tolerance and Long-term Outcomes Observational study) Study Group Identifying patients at risk for microalbuminuria via interaction of the components of the metabolic syndrome: a cross-sectional analytic study Clin J Am Soc Nephrol 2 2007 984 991
46. Y.I. Kim, C.H. Kim, and C.S. Choi Microalbuminuria is associated with the insulin resistance syndrome independent of hypertension and type 2 diabetes in the Korean population Diabetes Res Clin Pract 52 2001 145 152 (Pubitemid 32366484)
47. H. Suzuki, M. Fukushima, and M. Usami IGT with fasting hyperglycemia is more strongly associated with microalbuminuria than IGT without fasting hyperglycemia Diabetes Res Clin Pract 64 2004 213 219 (Pubitemid 38582014)
48. R.J. Tapp, J.E. Shaw, and P.Z. Zimmet Albuminuria is evident in early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) Am J Kidney Dis 44 2004 792 798 (Pubitemid 39445910)
49. E.L. Barr, P.Z. Zimmet, and T.A. Welborn Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) Circulation 116 2007 151 157 (Pubitemid 47057520)
50. Y.S. Levitzky, M.J. Pencina, and R.B. D'Agostino Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study J Am Coll Cardiol 51 2008 264 270
51. J.L. Chaisson Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial Endocr Pract 12 Suppl 1 2006 25 30
52. H.C. Gerstein, S. Yusuf, and J. Bosch DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial Lancet 368 2006 1096 1105 Erratum in: Lancet. 2006;368:1770
53. F.B. Hu, M.J. Stampfer, and S.M. Haffner Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes Diabetes Care 26 2002 688 696
54. W.M. Hsueh, L. Orloski, and K. Wyne Prediabetes: the importance of early identification and intervention Postgrad Med 122 4 2010 129 143
55. American Diabetes Association (ADA) Standards of medical care in diabetes - 2011 Diabetes Care 34 Suppl 1 2011 S62 S69
56. A.J. Garber, M.J. Abrahamson, and J.I. Barzilay AACE comprehensive diabetes management algorithm 2013 Endocr Pract 19 2013 327 336
57. D.M. Nathan, M.B. Davidson, and R.A. DeFronzo American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care Diabetes Care 30 2007 753 759 (Pubitemid 46354366)
58. J. Tuomilehto, J. Lindström, and J.G. Eriksson Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 344 2001 1343 1350 (Pubitemid 32378388)
59. X.R. Pan, G.W. Li, and Y.H. Hu Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and diabetes study Diabetes Care 20 1997 537 544
60. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
61. A.J. Garber, Y. Handelsman, and D. Einhorn Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists Endocr Pract 14 2008 933 946
62. J.L. Chiasson, R.G. Josse, R. Gomis STOP-NIDDM Trial Research Group Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial JAMA 290 2003 486 494 (Pubitemid 37430502)
63. R.A. DeFronzo, D. Tripathy, and D.C. Schwenke Pioglitazone for diabetes prevention in impaired glucose tolerance N Engl J Med 364 2011 1104 1115
64. GlaxoSmithKline. Avandia. Highlights of prescribing information; May 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 021071s039lbl.pdf. Accessed May 8, 2013.
65. Takeda Pharmaceuticals America, Inc. Actos. August 2007. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/021073s031lbl.pdf. Accessed May 8, 2013.
66. U.S. Food and Drug Administration (FDA). FDA drug safety communication: updated Risk Evaluation and Mitigation Strategy (REMS) to restrict access to rosiglitazone-containing medicines including Avandia, Avandamet, and Avandaryl. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm255005.htm. Accessed May 8, 2013.
67. NAVIGATOR Study Group Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med 362 2010 1477 1490
68. Centers for Disease Control and Prevention (CDC) Self-reported prediabetes and risk-reduction activities - United States, 2006 MMWR Morb Mortal Wkly Rep 57 2008 1203 1205
69. World Health Organization/International Diabetes Federation (WHO/IDF). Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. 2006. Available at: http://whqlibdoc.who.int/publications/2006/9241594934-eng. pdf. Accessed May 8, 2013.
70. 1c) in the diagnosis of diabetes mellitus. Available at: http://www.who.int/diabetes/publications/report-hba1c-2011.pdf. Accessed May 8, 2013.
71. M.I. Harris, R. Klein, T.A. Welborn, and M.W. Knuiman Onset of NIDDM occurs at least 4-7 years before clinical diagnosis Diabetes Care 15 1992 815 825
72. UK Prospective Diabetes Study (UKPDS) Group The UK Prospective Diabetes Study 30. Diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors Arch Ophthalmol 116 1998 670 677
73. D.H. Ryan, M.A. Espeland, G.D. Foster Look AHEAD Research Group Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes Control Clin Trials 24 2003 610 628
74. D.M. Nathan, J.B. Buse, and M.B. Davidson Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 2009 193 203
75. S. Bolen, L. Feldman, and J. Vassy Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus Ann Intern Med 147 2007 386 399 (Pubitemid 351664540)
76. Bristol-Myers Squibb Company. Glucophage® package insert. Available at: http://packageinserts.bms.com/pi/pi-glucophage.pdf. Accessed May 8, 2013.
77. S.E. Inzucchi, R.M. Besgenstal, and J.B. Buse Management of hyperglycemia in type 2 diabetes: a patient-centered approach Diabetes Care 35 2012 1364 1379
78. T. Bailey Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statment and AACE/ACE algorithm Am J Med 126 Suppl 2013 S10 S20
79. A. Qaseem, L.L. Humphrey, D.E. Sweet Clinical Guidelines Committee of the American College of Physicians Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians Ann Intern Med 156 2012 218 231
80. Y. Handelsman, J.I. Mechanick, and L. Blonde AACE Task Force for Developing Diabetes Comprehensive Care Plan American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan Endocr Pract 17 Suppl 2 2011 1 53